Disc Medicine Inc
For the period ended Dec 31, 2024. Filed Feb 27, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 27, 2025
IRON$84.64+4.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
(In thousands)
| Year EndedDecember 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash flows from operating activities | ||
| Net loss | $(109,357) | $(76,429) |
| Adjustments to reconcile net loss to net cash used in operations: | ||
| Depreciation and amortization | 156 | 100 |
| Stock-based compensation | 16,815 | 5,530 |
| Amortization/accretion of investment securities | (5,304) | — |
| Non-cash lease expense | 433 | 290 |
| Non-cash interest expense | 127 | — |
| Other non-cash items | (27) | — |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | 1,571 | (1,166) |
| Accounts payable | (4,681) | (3,741) |
| Accrued external research and development expenses | 5,155 | 169 |
| Other accrued expenses | 1,681 | 1,839 |
| Operating lease liabilities | (495) | (54) |
| Net cash used in operating activities | (93,926) | (73,462) |
| Cash flows from investing activities | ||
| Purchases of property and equipment | (505) | (89) |
| Purchases of marketable securities | (386,627) | — |
| Maturities of marketable securities | 94,800 | — |
| Net cash used in investing activities | (292,332) | (89) |
| Cash flows from financing activities | ||
| Proceeds from issuance of long-term debt, net of issuance costs paid | 28,988 | — |
| Payment of debt issuance costs | (1,393) | — |
| Proceeds from sale of common stock in offerings, net of issuance costs paid | 172,512 | 199,078 |
| Proceeds from sale of pre-funded warrants in offerings, net of issuance costs paid | — | 37,579 |
| Proceeds from sale of common stock in at-the-market offerings, net of issuance costs paid | 14,790 | — |
| Proceeds from stock option exercises | 2,976 | 2,722 |
| Contributions from employee stock purchase plan | 441 | — |
| Net cash provided by financing activities | 218,314 | 239,379 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | (167,944) | 165,828 |
| Cash, cash equivalents and restricted cash, beginning of period | 360,616 | 194,788 |
| Cash, cash equivalents and restricted cash, end of period | $192,672 | $360,616 |
(In thousands)
| Year EndedDecember 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Supplemental cash flow information | ||
| Cash paid for income taxes | $299 | $112 |
| Cash paid for interest | $198 | $— |
| Cash paid for amounts included in the measurement of operating lease liabilities | $718 | $186 |
| Supplemental disclosure of non-cash activities | ||
| Purchases of property and equipment included in accounts payable and accrued expenses | $245 | $13 |
| Right-of-use assets obtained in exchange for new operating lease liabilities | $— | $1,106 |
| Net increase (decrease) in right-of-use assets related to lease modifications and reassessment events | $72 | $(317) |
| Net increase (decrease) in operating lease liabilities related to lease modifications and reassessment events | $72 | $(287) |
| Deferred issuance costs on sale of pre-funded warrants in registered direct offering included in accounts payable and accrued expenses | $— | $225 |
| Receivable for proceeds from stock option exercises included in other current assets | $114 | $41 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.